Application DetailsThis antibody is recommended for WB and ELISA. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetTranscription factor AP-2-beta (AP2-beta)
SpecificitySpecificity has been confirmed by WB and direct ELISA against the antigen. Human. Other species have not been tested.
Target Host SpeciesHuman
Species ReactivityHuman
Antibody HostMouse
Antibody TypeMonoclonal
Antibody IsotypeIgG
Clone Name3G5-1D11
ConjugateUnconjugated
Immunogen DescriptionRecombinant human AP2-beta (amino acids 12-460) with GST tag.
Purity DescriptionProtein G purified immunoglobulin
FormatLyophilized from PBS pH 7.2
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 100 µL sterile-filtered, ultrapure water. Centrifuge to remove any insoluble material.
Storage InstructionsAfter reconstitution keep aliquots at -20°C for higher stability or at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for additional stability. Avoid repetitive freeze/thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesTranscription factor AP2-beta; Activating enhancer-binding protein 2 beta; TFAP2B
AP2-beta is a sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes during early development. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes. AP2-beta appears to be required for normal face and limb development and for proper termnal differentiation and function of renal tubular epithelia. Binds DNA as a dimer. It can form homodimers or heterodimers with other AP-2 family members. Defects in AP2-beta are the cause of Char syndrome (CHAR) which is characterised by patent ductus anteriosus (PDA), facial dysmorphism and hand anomalies.